Scienza e Tecnologia
Vidac Pharma Ltd.: New Chemical Entities Patent Granted
Vidac Pharma was founded in Israel in 2012 by Dr
Max Herzberg and aims to develop anti-cancer drugs based on restoring normal cellular metabolism. Cancer cells are characterized by a high rate of glycolysis and by suppressed apoptosis (programmed death) both of which favorizes high cellular reproduction and Tumor formation. Vidac's platform technology restores normal glycolysis and triggers apoptosis in these malignant cells. As normal cells are not subject to overexpression of HK2 they are not affected by Vidac's drugs. Vidac's lead drug, VDA-1102, has successfully completed a Phase
2b clinical trial in actinic keratosis (AK) under an IND from the FDA and is presently in a Phase 2a clinical trial in CTCL in
Israel . The company's strategic intellectual property portfolio covers broadly its general approach using the TopostericTM effect avoiding enzymatic cell mis-location.
Logo - https://mma.prnewswire.com/media/1490442/Vidac_Pharma_Logo.jpg
For further information about Vidac Pharma:
Max Herzberg , PhD. Active Chairman of the Board
info@vidacpharma.com
www.vidacpharma.com